Search

Your search keyword '"Zang, Rongyu"' showing total 209 results
Start Over Author "Zang, Rongyu"
209 results on '"Zang, Rongyu"'

2. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

Author

Li, Huayi, Peng, Zikun, Zhu, Jianqing, Zhao, Weidong, Huang, Yi, An, Ruifang, Zheng, Hong, Qu, Pengpeng, Wang, Li, Zhou, Qi, Wang, Danbo, Lou, Ge, Wang, Jing, Wang, Ke, Kong, Beihua, Xie, Xing, Yin, Rutie, Low, John, Rozita, Abdul Malik, Sen, Lim Chun, Meng, Yong Chee, Kiong, Kho Swee, Liu, Jihong, Liang, Zhiqing, Lv, Weiguo, Zhu, Yaping, Hu, Weiguo, Sun, Wei, Su, Jingya, Wang, Qiqi, Zang, Rongyu, Ma, Ding, and Gao, Qinglei

Published
2024
Full Text
View/download PDF

3. Primary Prevention of Ovarian Cancer

Author

SHEN Li'na and ZANG Rongyu

Subjects
ovarian cancer, primary prevention, screening, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Ovarian cancer is the most lethal malignancy of the female genital tract. Genetic predisposition, usage of hormone, relative disease and reproduction, and lifestyle factors are possible risk factors for ovarian cancer. Women can be stratified into high risk and general populations according to the ovarian cancer risk. Screening and prevention were reviewed for the two populations. Population-based trials in the general population have not demonstrated that screening improves early detection or survival. Strengthening the awareness of tumor prevention and conducting effective screening and prevention in the high-risk population are cost-effective methods to reduce the incidence and mortality of ovarian cancer.

Published
2023
Full Text
View/download PDF

4. Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy

Author

ZANG Rongyu

Subjects
ovarian cancer, tertiary prevention, parp inhibitors, chemoresistance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The tertiary prevention approaches of ovarian cancer include whole-person care, training of the patients to cooperate with physicians in the periods of treatment and follow-up, training program of the qualified surgeons, and recognition of biological behavior changes of relapse after PARPi therapy. Surgery remains the cornerstone in the management of ovarian cancer, but the role of surgery after PARPi remains unknown. Recently, the US FDA withdrew the indication of three PARP inhibitors in the treatment of recurrent ovarian cancer with ≥3 lines of chemotherapy because of their ≥30% increased death risk. Thus, we should pay more attention to the biological recurrence and chemoresistance caused by PARP inhibitors and post-progression survival in ovarian cancer.

Published
2023
Full Text
View/download PDF

5. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Mahner, Sven, Reuss, Alexander, du Bois, Andreas, Grimm, Christoph, Marth, Christian, Berger, Regina, Concin, Nicole, Chang, Ting-Chang, Ochiai, Kazunori, Gebski, Val, Davis, Alison, Beale, Philip, Vergote, Ignace, Kridelka, Frédéric, Denys, Hannelore, Vandecaveye, Vincent, Candido dos Reis, Francisco Jose, Del Pilar Estevez Diz, Maria, Stuart, Gavin, MacKay, Helen, Carey, Mark, Cibula, David, Dundr (path), Pavel, Dorigo, Oliver, Berek, Jonathan, O'Donnell, Dearbhaile, Saadeh, Abu, Boere, Ingrid, Lok, Christianne, Coronado, Pluvio, Ottevanger, Nelleke, Tan, David SP, Ng, Joseph, Gonzalez Martin, Antonio, Oaknin, Ana, Poveda, Andres, Perez Fidalgo, Alejandro, Rauh-Hain, Alejandro, Lu, Karen, López-Zavala, Carlos, Gómez-García, Eva María, Ray-Coquard, Isabelle, Paoletti, Xavier, Kurtz, Jean-Emmanuel, Joly, Florence, Votan, Bénédicte, Bookman, Michael, Moore, Kathleen, Arend, Rebecca, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Hasegawa, Kosei, Bruchim, Ilan, Tsoref, Dalia, Oda, Katsutoshi, Okamoto, Aikou, Enomoto, Takayuki, Michel, Dayana, Kim, Hee-Seung, Lee, Jung-Yun, Mukhopadhyay, Asima, Katsaros, Dionyssios, Colombo, Nicoletta, Pignata, Sandro, Lorusso, Domenica, Scambia, Giovanni, Kohn, Elise, Lee, Jung-Min, McNeish, Iain, Nicum, Shibani, Farrelly, Laura, Sehouli, Jalid, Keller, Maren, Braicu, Elena, Bjørge, Line, Mirza, Mansoor Raza, Auranen, Annika, Welch, Stephen, Oza, Amit M, Heinzelmann, Viola, Gourley, Charlie, Roxburgh, Patricia, Herrington, C Simon, Glasspool, Ros, Zang, Rongyu, Zhu, Jianqing, Gonzalez-Martin, Antonio, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Stuart, Gavin C E, and Bookman, Michael A

Published
2022
Full Text
View/download PDF

9. Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.

Author

Gao, Qing-lei, primary, Zhu, Jianqing, additional, Zhao, Weidong, additional, Huang, Yi, additional, An, Ruifang, additional, Zheng, Hong, additional, Qu, Pengpeng, additional, Wang, Li, additional, Zhou, Qi, additional, Wang, Danbo, additional, Lou, Ge, additional, Wang, Jing, additional, Low, John, additional, Kong, Beihua, additional, Yin, Rutie, additional, Lv, Weiguo, additional, Liu, Jihong, additional, Sun, Wei, additional, Zang, Rongyu, additional, and Ma, Ding, additional

Published
2024
Full Text
View/download PDF

10. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.

Author

Zang, Rongyu, primary, Zhu, Jianqing, additional, Liu, Jihong, additional, Jiang, Rong, additional, Cheng, Xi, additional, Chen, Yulian, additional, Jia, Huixun, additional, Shi, Tingyan, additional, Guo, Yi, additional, Feng, Yanling, additional, Tu, Dongsheng, additional, Zhang, Yuqin, additional, Huang, Xiao, additional, Jiang, Shiyang, additional, Gao, Wen, additional, Yang, Huijuan, additional, and Zhang, Ping, additional

Published
2024
Full Text
View/download PDF

13. Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer

Author

Shen, Peiye, primary, Ye, Kaiyan, additional, Xiang, Huaijiang, additional, Zhang, Zhenfeng, additional, He, Qinyang, additional, Zhang, Xiao, additional, Cai, Mei-Chun, additional, Chen, Junfei, additional, Sun, Yunheng, additional, Lin, Lifeng, additional, Qi, Chunting, additional, Zhang, Meiying, additional, Cheung, Lydia W. T., additional, Shi, Tingyan, additional, Yin, Xia, additional, Li, Ying, additional, Di, Wen, additional, Zang, Rongyu, additional, Tan, Li, additional, and Zhuang, Guanglei, additional

Published
2023
Full Text
View/download PDF

16. Supplementary Table from Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)

Author

Gao, Qinglei, primary, Zhu, Jianqing, primary, Zhao, Weidong, primary, Huang, Yi, primary, An, Ruifang, primary, Zheng, Hong, primary, Qu, Pengpeng, primary, Wang, Li, primary, Zhou, Qi, primary, Wang, Danbo, primary, Lou, Ge, primary, Wang, Jing, primary, Wang, Ke, primary, Low, John, primary, Kong, Beihua, primary, Rozita, Abdul Malik, primary, Sen, Lim Chun, primary, Yin, Rutie, primary, Xie, Xing, primary, Liu, Jihong, primary, Sun, Wei, primary, Su, Jingya, primary, Zhang, Chunyi, primary, Zang, Rongyu, primary, and Ma, Ding, primary

Published
2023
Full Text
View/download PDF

22. 2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial

Author

Fotopoulou, Christina, primary, Sehouli, Jalid, additional, Vergote, Ignace, additional, Reuss, Alexander, additional, Leheurteur, Marianne, additional, Hilpert, Felix, additional, Savoye, Aude-Marie, additional, Greggi, Stefano, additional, Vernersson, Johanna, additional, Resch, Benoît, additional, Gatineau, Michel, additional, Levêque, Jean, additional, Zang, Rongyu, additional, Jensen, Pernille T, additional, Kim, Jae W, additional, Santiago, Domingo, additional, Raspagliesi, Francesco, additional, Peen, Ulla, additional, Bois, Andreas du, additional, and Harter, Philipp, additional

Published
2022
Full Text
View/download PDF

24. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Vergote, Ignace, primary, Gonzalez-Martin, Antonio, additional, Lorusso, Domenica, additional, Gourley, Charlie, additional, Mirza, Mansoor Raza, additional, Kurtz, Jean-Emmanuel, additional, Okamoto, Aikou, additional, Moore, Kathleen, additional, Kridelka, Frédéric, additional, McNeish, Iain, additional, Reuss, Alexander, additional, Votan, Bénédicte, additional, du Bois, Andreas, additional, Mahner, Sven, additional, Ray-Coquard, Isabelle, additional, Kohn, Elise C, additional, Berek, Jonathan S, additional, Tan, David S P, additional, Colombo, Nicoletta, additional, Zang, Rongyu, additional, Concin, Nicole, additional, O'Donnell, Dearbhaile, additional, Rauh-Hain, Alejandro, additional, Herrington, C Simon, additional, Marth, Christian, additional, Poveda, Andres, additional, Fujiwara, Keiichi, additional, Stuart, Gavin C E, additional, Oza, Amit M, additional, Bookman, Michael A, additional, Grimm, Christoph, additional, Berger, Regina, additional, Chang, Ting-Chang, additional, Ochiai, Kazunori, additional, Gebski, Val, additional, Davis, Alison, additional, Beale, Philip, additional, Vergote, Ignace, additional, Denys, Hannelore, additional, Vandecaveye, Vincent, additional, Candido dos Reis, Francisco Jose, additional, Del Pilar Estevez Diz, Maria, additional, Stuart, Gavin, additional, MacKay, Helen, additional, Carey, Mark, additional, Cibula, David, additional, Dundr (path), Pavel, additional, Dorigo, Oliver, additional, Berek, Jonathan, additional, Saadeh, Abu, additional, Boere, Ingrid, additional, Lok, Christianne, additional, Coronado, Pluvio, additional, Ottevanger, Nelleke, additional, Tan, David SP, additional, Ng, Joseph, additional, Gonzalez Martin, Antonio, additional, Oaknin, Ana, additional, Perez Fidalgo, Alejandro, additional, Lu, Karen, additional, López-Zavala, Carlos, additional, Gómez-García, Eva María, additional, Paoletti, Xavier, additional, Joly, Florence, additional, Bookman, Michael, additional, Arend, Rebecca, additional, Fujiwara, Hiroyuki, additional, Hasegawa, Kosei, additional, Bruchim, Ilan, additional, Tsoref, Dalia, additional, Oda, Katsutoshi, additional, Enomoto, Takayuki, additional, Michel, Dayana, additional, Kim, Hee-Seung, additional, Lee, Jung-Yun, additional, Mukhopadhyay, Asima, additional, Katsaros, Dionyssios, additional, Pignata, Sandro, additional, Scambia, Giovanni, additional, Kohn, Elise, additional, Lee, Jung-Min, additional, Nicum, Shibani, additional, Farrelly, Laura, additional, Sehouli, Jalid, additional, Keller, Maren, additional, Braicu, Elena, additional, Bjørge, Line, additional, Auranen, Annika, additional, Welch, Stephen, additional, Heinzelmann, Viola, additional, Roxburgh, Patricia, additional, Glasspool, Ros, additional, and Zhu, Jianqing, additional

Published
2022
Full Text
View/download PDF

25. Angiogenic Burst After Parp Inhibitor Maintenance Therapy in Relapsed Ovarian Cancer: A Case Report

Author

Lin, Lifeng, Luo, Rongkui, Gao, Wen, Zhang, Ping, Hou, Yingyong, Zang, Rongyu, and Shi, Tingyan

Subjects
pathology_pathobiology
Abstract

In the post-PARP inhibitor era, potential changes in tumor biology after maintenance therapy have not been well investigated in recurrent ovarian cancer. We reported a case with alterations in the clinical and histological features of multiple relapsed disease associated with PARP inhibitor maintenance therapy. The patient with high-grade serous carcinoma exhibited BRCA wildtype and homologous recombination proficiency status, and suffered from three recurrences and surgeries accordingly. Olaparib maintenance had been used during the second-line therapy. We compared the differences in clinics and pathology among three recurrences and relapsed lesions. Disease-free survivals were dramatically decreased after the exposure to olaparib. At exploration of quaternary cytoreduction, the relapsed tumor was characterized by a carcinomatosis-like metastasis pattern and an easy tendency of bleeding. Tumor cytopathological changes and alterations were observed in both the tumoral and non-tumoral stroma, among relapsed tumor tissues derived from secondary, tertiary and quaternary cytoreduction. Histopathology indicated hemorrhage, necrosis, atypical tumor cells, massive angiogenesis, and decreased CD8+ tumor-infiltrating lymphocytes, particularly in the third relapsed disease. To our knowledge, this is the first report to show a unique metastatic pattern of angiogenic burst after PARP inhibitor maintenance therapy in ovarian cancer, which seemed to trigger invasive tumor growth and immune suppression. Further prospective studies and translational research focusing cytoreductive surgery after PARP inhibitor could progressively lead to an understanding of the biological behavior and metastatic patterns.

Published
2022
Full Text
View/download PDF

29. Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma

Author

Hu, Dianxing, primary, Guo, Ensong, additional, Yang, Bin, additional, Qin, Xu, additional, Fu, Yu, additional, Fan, Junpeng, additional, Zhuang, Xucui, additional, Yao, Qianqian, additional, Lu, Funian, additional, Li, Wenting, additional, Xiao, Rourou, additional, Wu, Xue, additional, Yang, Xiaohang, additional, Wang, Zizhuo, additional, Liu, Chen, additional, You, Lixin, additional, Zang, Rongyu, additional, Zhou, Qi, additional, Zhao, Weidong, additional, Chen, Gang, additional, and Sun, Chaoyang, additional

Published
2022
Full Text
View/download PDF

31. Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.

Author

Ma, Ding, primary, Gao, Qing-lei, additional, Zhu, Jianqing, additional, Zhao, Weidong, additional, Huang, Yi, additional, An, Ruifang, additional, Zheng, Hong, additional, Qu, Pengpeng, additional, Wang, Li, additional, Zhou, Qi, additional, Wang, Danbo, additional, Lou, Ge, additional, Wang, Jing, additional, Low, John, additional, Kong, Beihua, additional, Yin, Rutie, additional, Xie, Xing, additional, Liu, Jihong, additional, Sun, Wei, additional, and Zang, Rongyu, additional

Published
2022
Full Text
View/download PDF

33. Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial.

Author

Sehouli, Jalid, primary, Fotopoulou, Christina, additional, Vergote, Ignace, additional, Reuss, Alexander, additional, Ferron, Gwenael, additional, Meier, Werner, additional, Greggi, Stefano, additional, Mosgaard, Berit J., additional, Selle, Frederic, additional, Guyon, Frederic, additional, Pomel, Christophe, additional, Lecuru, Fabrice, additional, Zang, Rongyu, additional, Hellmann, Kristina, additional, Kim, Jae-Weon, additional, Romeo, Margarita, additional, Raspagliesi, Francesco, additional, Eyjólfsdóttir, Brynhildur, additional, Du Bois, Andreas, additional, and Harter, Philipp, additional

Published
2022
Full Text
View/download PDF

36. Clinical research in ovarian cancer:consensus recommendations from the Gynecologic Cancer InterGroup

Author

Vergote, Ignace, Gonzalez-Martin, Antonio, Lorusso, Domenica, Gourley, Charlie, Mirza, Mansoor Raza, Kurtz, Jean Emmanuel, Okamoto, Aikou, Moore, Kathleen, Kridelka, Frédéric, McNeish, Iain, Reuss, Alexander, Votan, Bénédicte, du Bois, Andreas, Mahner, Sven, Ray-Coquard, Isabelle, Kohn, Elise C., Berek, Jonathan S., Tan, David S.P., Colombo, Nicoletta, Zang, Rongyu, Concin, Nicole, O'Donnell, Dearbhaile, Rauh-Hain, Alejandro, Herrington, C. Simon, Marth, Christian, Poveda, Andres, Fujiwara, Keiichi, Stuart, Gavin C.E., Oza, Amit M., Bookman, Michael A., Vergote, Ignace, Gonzalez-Martin, Antonio, Lorusso, Domenica, Gourley, Charlie, Mirza, Mansoor Raza, Kurtz, Jean Emmanuel, Okamoto, Aikou, Moore, Kathleen, Kridelka, Frédéric, McNeish, Iain, Reuss, Alexander, Votan, Bénédicte, du Bois, Andreas, Mahner, Sven, Ray-Coquard, Isabelle, Kohn, Elise C., Berek, Jonathan S., Tan, David S.P., Colombo, Nicoletta, Zang, Rongyu, Concin, Nicole, O'Donnell, Dearbhaile, Rauh-Hain, Alejandro, Herrington, C. Simon, Marth, Christian, Poveda, Andres, Fujiwara, Keiichi, Stuart, Gavin C.E., Oza, Amit M., and Bookman, Michael A.

Abstract

The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.

Published
2022

37. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Vergote, I, Gonzalez-Martin, A, Lorusso, D, Gourley, C, Mirza, M, Kurtz, J, Okamoto, A, Moore, K, Kridelka, F, Mcneish, I, Reuss, A, Votan, B, du Bois, A, Mahner, S, Ray-Coquard, I, Kohn, E, Berek, J, Tan, D, Colombo, N, Zang, R, Concin, N, O'Donnell, D, Rauh-Hain, A, Herrington, C, Marth, C, Poveda, A, Fujiwara, K, Stuart, G, Oza, A, Bookman, M, Vergote, Ignace, Gonzalez-Martin, Antonio, Lorusso, Domenica, Gourley, Charlie, Mirza, Mansoor Raza, Kurtz, Jean-Emmanuel, Okamoto, Aikou, Moore, Kathleen, Kridelka, Frédéric, McNeish, Iain, Reuss, Alexander, Votan, Bénédicte, du Bois, Andreas, Mahner, Sven, Ray-Coquard, Isabelle, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Colombo, Nicoletta, Zang, Rongyu, Concin, Nicole, O'Donnell, Dearbhaile, Rauh-Hain, Alejandro, Herrington, C Simon, Marth, Christian, Poveda, Andres, Fujiwara, Keiichi, Stuart, Gavin C E, Oza, Amit M, Bookman, Michael A, Vergote, I, Gonzalez-Martin, A, Lorusso, D, Gourley, C, Mirza, M, Kurtz, J, Okamoto, A, Moore, K, Kridelka, F, Mcneish, I, Reuss, A, Votan, B, du Bois, A, Mahner, S, Ray-Coquard, I, Kohn, E, Berek, J, Tan, D, Colombo, N, Zang, R, Concin, N, O'Donnell, D, Rauh-Hain, A, Herrington, C, Marth, C, Poveda, A, Fujiwara, K, Stuart, G, Oza, A, Bookman, M, Vergote, Ignace, Gonzalez-Martin, Antonio, Lorusso, Domenica, Gourley, Charlie, Mirza, Mansoor Raza, Kurtz, Jean-Emmanuel, Okamoto, Aikou, Moore, Kathleen, Kridelka, Frédéric, McNeish, Iain, Reuss, Alexander, Votan, Bénédicte, du Bois, Andreas, Mahner, Sven, Ray-Coquard, Isabelle, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Colombo, Nicoletta, Zang, Rongyu, Concin, Nicole, O'Donnell, Dearbhaile, Rauh-Hain, Alejandro, Herrington, C Simon, Marth, Christian, Poveda, Andres, Fujiwara, Keiichi, Stuart, Gavin C E, Oza, Amit M, and Bookman, Michael A

Abstract

The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.

Published
2022

40. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

Author

Harter, Philipp, primary, Sehouli, Jalid, additional, Vergote, Ignace, additional, Ferron, Gwenael, additional, Reuss, Alexander, additional, Meier, Werner, additional, Greggi, Stefano, additional, Mosgard, Berit J., additional, Selle, Frederic, additional, Guyon, Frederic, additional, Pomel, Christophe, additional, Lécuru, Fabrice, additional, Zang, Rongyu, additional, Avall-Lundqvist, Elisabeth, additional, Kim, Jae‐Weon, additional, Ponce, Jordi, additional, Raspagliesi, Francesco, additional, Kristensen, Gunnar, additional, Classe, Jean-Marc, additional, Hillemanns, Peter, additional, Jensen, Pernille, additional, Hasenburg, Annette, additional, Ghaem-Maghami, Sadaf, additional, Mirza, Mansoor R., additional, Lund, Bente, additional, Reinthaller, Alexander, additional, Santaballa, Ana, additional, Olaitan, Adeola, additional, Hilpert, Felix, additional, and du Bois, Andreas, additional

Published
2022
Full Text
View/download PDF

41. Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)

Author

Gao, Qinglei, primary, Zhu, Jianqing, additional, Zhao, Weidong, additional, Huang, Yi, additional, An, Ruifang, additional, Zheng, Hong, additional, Qu, Pengpeng, additional, Wang, Li, additional, Zhou, Qi, additional, Wang, Danbo, additional, Lou, Ge, additional, Wang, Jing, additional, Wang, Ke, additional, Low, John, additional, Kong, Beihua, additional, Rozita, Abdul Malik, additional, Sen, Lim Chun, additional, Yin, Rutie, additional, Xie, Xing, additional, Liu, Jihong, additional, Sun, Wei, additional, Su, Jingya, additional, Zhang, Chunyi, additional, Zang, Rongyu, additional, and Ma, Ding, additional

Published
2022
Full Text
View/download PDF

42. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

Author

Harter, Philipp, Sehouli, Jalid, Vergote, Ignace, Ferron, Gwenael, Reuss, Alexander, Meier, Werner, Greggi, Stefano, Mosgard, Berit J, Selle, Frederic, Guyon, Frédéric, Pomel, Christophe, Lécuru, Fabrice, Zang, Rongyu, Avall-Lundqvist, Elisabeth, Kim, Jae-Weon, Ponce, Jordi, Raspagliesi, Francesco, Kristensen, Gunnar, Classe, Jean-Marc, Hillemanns, Peter, Jensen, Pernille, Hasenburg, Annette, Ghaem-Maghami, Sadaf, Mirza, Mansoor R, Lund, Bente, Reinthaller, Alexander, Santaballa, Ana, Olaitan, Adeola, Hilpert, Felix, du Bois, Andreas, S Buchholz, A Burges, U Canzler, D Denschlag, A El-Balat, G Emons, R Felberbaum, N de Gregorio, M Gropp-Meier, V Hanf, L Hanker, R Hils, C Kurzeder, B Lampe, A Mustea, M Schmidt, R Schutz, M Weigel, S Weiser, A Zorr, C Marth, E Petru, T Scholl, M Beltran, I Bover, A Gomez di Laino, N Lainez, S Martinez, A Poveda Velasco, M Romeo, H Crouet, E de Gournay, G Deplanque, P Follana, A Floquet, D Lanvin, J Leveque, E Pujade-Lauraine, N Raban, B Resch, A M Savoye, G Aletti, G Giorda, F Landoni, C Scaffa, J Abu, F Alexander-Sefre, D Barton, S Butler-Manuel, R Clayton, R Crawford, T Duncan, A El-Ghobashy, C Fotopoulou, M Hall, C Intrivici, A Lawrence, D Luesley, R Naik, A Nordin, J Tidy, L Fokdahl, A Hofsjö, P Kjolhede, B Eyjolfsdottir, Z Y Dai, P Zhang, B Aminossadati, M Hahmann, C Nasemann, S Yahiaoui, M Wittenberg, C Schade-Brittinger, G Elser, D Reddig, M Kuncke, S Polleis, Y Mattukat, A Riha, R Berger, J de Roover, B Kaur, J Crook, F Nepote, B Votan, M Andriamamonjy, J Bryce, S Ristinge, Philipp, H, Jalid, S, Ignace, V, Gwenael, F, Alexander, R, Werner, M, Stefano, G, Berit J, M, Frederic, S, Frédéric, G, Christophe, P, Fabrice, L, Rongyu, Z, Elisabeth, A, Jae-Weon, K, Jordi, P, Francesco, R, Gunnar, K, Jean-Marc, C, Peter, H, Pernille, J, Annette, H, Sadaf, G, Mansoor R, M, Bente, L, Ana, S, Adeola, O, Felix, H, Andreas, D, Buchholz, S, Burges, A, Canzler, U, Denschlag, D, El-Balat, A, Emons, G, Felberbaum, R, de Gregorio, N, Gropp-Meier, M, Hanf, V, Hanker, L, Hils, R, Kurzeder, C, Lampe, B, Mustea, A, Schmidt, M, Schutz, R, Weigel, M, Weiser, S, Zorr, A, Marth, C, Petru, E, Scholl, T, Beltran, M, Bover, I, Gomez di Laino, A, Lainez, N, Martinez, S, Poveda Velasco, A, Romeo, M, Crouet, H, de Gournay, E, Deplanque, G, Follana, P, Floquet, A, Lanvin, D, Leveque, J, Pujade-Lauraine, E, Raban, N, Resch, B, M Savoye, A, Aletti, G, Giorda, G, Landoni, F, Scaffa, C, Abu, J, Alexander-Sefre, F, Barton, D, Butler-Manuel, S, Clayton, R, Crawford, R, Duncan, T, El-Ghobashy, A, Fotopoulou, C, Hall, M, Intrivici, C, Lawrence, A, Luesley, D, Naik, R, Nordin, A, Tidy, J, Fokdahl, L, Hofsjö, A, Kjolhede, P, Eyjolfsdottir, B, Y Dai, Z, Zhang, P, Aminossadati, B, Hahmann, M, Nasemann, C, Yahiaoui, S, Wittenberg, M, Schade-Brittinger, C, Elser, G, Reddig, D, Kuncke, M, Polleis, S, Mattukat, Y, Riha, A, Berger, R, de Roover, J, Kaur, B, Crook, J, Nepote, F, Votan, B, Andriamamonjy, M, Bryce, J, and Ristinge, S

Subjects
EPITHELIAL OVARIAN, Oncology, medicine.medical_specialty, BEVACIZUMAB, MULTICENTER, Antineoplastic Agents, PACLITAXEL, Systemic therapy, law.invention, Antineoplastic Agent, Randomized controlled trial, law, Internal medicine, Humans, Medicine, RECURRENT, Proportional Hazards Models, Aged, Ovarian Neoplasms, SECONDARY CYTOREDUCTION, business.industry, Ovarian Neoplasm, Antineoplastic Agents/therapeutic use, Obstetrics and Gynecology, Ovarian Neoplasms/drug therapy, Cytoreduction Surgical Procedures, General Medicine, CHEMOTHERAPY, Middle Aged, OPEN-LABEL, medicine.disease, Survival Analysis, Combined Modality Therapy, Neoplasm Recurrence, Local/drug therapy, Recurrent Ovarian Cancer, Proportional Hazards Model, Quality of Life, Female, Survival Analysi, Neoplasm Recurrence, Local, business, Cytoreductive surgery, Ovarian cancer, Human
Abstract

BACKGROUND: Treatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The role of secondary cytoreductive surgery is unclear. METHODS: We randomly assigned patients with recurrent ovarian cancer who had a first relapse after a platinum-free interval (an interval during which no platinum-based chemotherapy was used) of 6 months or more to undergo secondary cytoreductive surgery and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Patients were eligible if they presented with a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score, defined as an Eastern Cooperative Oncology Group performance-status score of 0 (on a 5-point scale, with higher scores indicating greater disability), ascites of less than 500 ml, and complete resection at initial surgery. A positive AGO score is used to identify patients in whom a complete resection might be achieved. The primary end point was overall survival. We also assessed quality of life and prognostic factors for survival. RESULTS: A total of 407 patients underwent randomization: 206 were assigned to cytoreductive surgery and chemotherapy, and 201 to chemotherapy alone. A complete resection was achieved in 75.5% of the patients in the surgery group who underwent the procedure. The median overall survival was 53.7 months in the surgery group and 46.0 months in the no-surgery group (hazard ratio for death, 0.75; 95% confidence interval, 0.59 to 0.96; P = 0.02). Patients with a complete resection had the most favorable outcome, with a median overall survival of 61.9 months. A benefit from surgery was seen in all analyses in subgroups according to prognostic factors. Quality-of-life measures through 1 year of follow-up did not differ between the two groups, and we observed no perioperative mortality within 30 days after surgery. CONCLUSIONS: In women with recurrent ovarian cancer, cytoreductive surgery followed by chemotherapy resulted in longer overall survival than chemotherapy alone. (Funded by the AGO Study Group and others; DESKTOP III ClinicalTrials.gov number, NCT01166737.).

Published
2021
Full Text
View/download PDF

44. Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Author

Shi, Tingyan, primary, Xiang, Libing, additional, Zhu, Jianqing, additional, Liu, Jihong, additional, Zhang, Ping, additional, Wang, Huaying, additional, Feng, Yanling, additional, Zhu, Tao, additional, Zhang, Yingli, additional, Yu, Aijun, additional, Jiang, Wei, additional, Wang, Xipeng, additional, Zhu, Yaping, additional, Wu, Sufang, additional, Teng, Yincheng, additional, Zhang, Jiejie, additional, Jiang, Rong, additional, Zhang, Wei, additional, Jia, Huixun, additional, and Zang, Rongyu, additional

Published
2022
Full Text
View/download PDF

45. Sodium nitrite (NaNO2) regulating myoglobin-mediated lipid oxidation in washed bovine mince.

Author

Zang, Rongyu, Zhu, Yanyan, Yu, Qunli, Han, Ling, Han, Mingshan, Lin, Liang, and Zuo, Xiufeng

Subjects
*MYOGLOBIN, *SODIUM nitrites, *LIPIDS, *OXIDATION, *FOOD preservatives, *BOS
Abstract

This study investigated the effect of NaNO2 on inhibiting myoglobin-mediated lipid oxidation in muscle using a washed bovine mince model. We measured various parameters, including TBARS and PV to determine lipid oxidation, non-heme iron release, protoporphyrin destruction, and nitrosylmyoglobin production. The results of the study showed that the addition of NaNO2 during myoglobin-mediated lipid oxidation significantly reduced the fading and lipid oxidation of washed muscle (p < 0.05). Additionally, the addition of NaNO2 reduced the release of non-heme iron and the degradation of protoporphyrin in myoglobin. Nitrosylmyoglobin was formed in the washed mince supplemented with NaNO2 and myoglobin. These findings suggest that NaNO2 can effectively inhibit the lipid oxidation process induced by myoglobin, which could be a crucial aspect of nitrite inhibition of lipid oxidation in cured meat products. Overall, the study provides evidence for the potential use of NaNO2 as a food preservative to prevent lipid oxidation in meat products. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results